Jing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jing Wang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Chao Li
Department of Cardiology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China
1 shared publication - Feng Tian
Department of Cardiology, Chinese PLA General Hospital, Beijing, China
1 shared publication - Guanhua Dou
Department of Cardiology, the Second Medical Centre
1 shared publication - Jing Jing
Department of Cardiology, the First Medical Center of PLA General Hospital, Beijing, China
1 shared publication - Jun Guo
Department of Cardiology, The Sixth Medical Center of PLA General Hospital, Haidian District, Beijing 100039, China
1 shared publication - Jun-Jie Yang
Department of Cardiology, Chinese PLA General Hospital, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 10 March 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (3) , 437
Machine Learning Model-Based Simple Clinical Information to Predict Decreased Left Atrial Appendage Flow Velocity
Background: Transesophageal echocardiography (TEE) is the first technique of choice for evaluating the left atrial appendage flow velocity (LAAV) in clinical practice, which may cause some complications. Therefore, clinicians require a simple applicable method to screen patients with decreased LAAV. Therefore, we investigated the feasibility and accuracy of a machine learning (ML) model to predict LAAV. Method: The analysis included patients with atrial fibrillation who visited the general hospital of PLA and underwent transesophageal echocardiography (TEE) between January 2017 and December 2020. Three machine learning algorithms were used to predict LAAV. The area under the receiver operating characteristic curve (AUC) was measured to evaluate diagnostic accuracy. Results: Of the 1039 subjects, 125 patients (12%) were determined as having decreased LAAV (LAAV < 25 cm/s). Patients with decreased LAAV were fatter and showed a higher prevalence of persistent AF, heart failure, hypertension, diabetes and stroke, and the decreased LAAV group had a larger left atrium diameter and a higher serum level of NT-pro BNP than the control group (p < 0.05). Three machine-learning models (SVM model, RF model, and KNN model) were developed to predict LAAV. In the test data, the RF model performs best (R = 0.608, AUC = 0.89) among the three models. A fivefold cross-validation scheme further verified the predictive ability of the RF model. In the RF model, NT-proBNP was the factor with the strongest impact. Conclusions: A machine learning model (Random Forest model)-based simple clinical information showed good performance in predicting LAAV. The tool for the screening of decreased LAAV patients may be very helpful in the risk classification of patients with a high risk of LAA thrombosis.
- 10 March 2022
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (3) , 437
Open AccessMachine Learning Model-Based Simple Clinical Information to Predict Decreased Left Atrial Appendage Flow Velocity
Background: Transesophageal echocardiography (TEE) is the first technique of choice for evaluating the left atrial appendage flow velocity (LAAV) in clinical practice, which may cause some complications. Therefore, clinicians require a simple applicable method to screen patients with decreased LAAV. Therefore, we investigated the feasibility and accuracy of a machine learning (ML) model to predict LAAV. Method: The analysis included patients with atrial fibrillation who visited the general hospital of PLA and underwent transesophageal echocardiography (TEE) between January 2017 and December 2020. Three machine learning algorithms were used to predict LAAV. The area under the receiver operating characteristic curve (AUC) was measured to evaluate diagnostic accuracy. Results: Of the 1039 subjects, 125 patients (12%) were determined as having decreased LAAV (LAAV < 25 cm/s). Patients with decreased LAAV were fatter and showed a higher prevalence of persistent AF, heart failure, hypertension, diabetes and stroke, and the decreased LAAV group had a larger left atrium diameter and a higher serum level of NT-pro BNP than the control group (p < 0.05). Three machine-learning models (SVM model, RF model, and KNN model) were developed to predict LAAV. In the test data, the RF model performs best (R = 0.608, AUC = 0.89) among the three models. A fivefold cross-validation scheme further verified the predictive ability of the RF model. In the RF model, NT-proBNP was the factor with the strongest impact. Conclusions: A machine learning model (Random Forest model)-based simple clinical information showed good performance in predicting LAAV. The tool for the screening of decreased LAAV patients may be very helpful in the risk classification of patients with a high risk of LAA thrombosis.
- Open Access
- 6 January 2016
- Published by Springer Nature in Trials
- Vol. 17 (1) , 1-8
Efficacy study of olmesartan medoxomil on coronary atherosclerosis progression and epicardial adipose tissue volume reduction in patients with coronary atherosclerosis detected by coronary computed tomography angiography: study protocol for a randomized controlled trial
Epicardial adipose tissue (EAT) is a newly discovered independent risk factor for coronary atherosclerosis. There is a scarcity of information on the reduction of EAT volume to reduce atherosclerosis risk. Coronary computed tomography angiography (CCTA) has emerged as a noninvasive imaging method for the analysis of coronary atherosclerosis and EAT volume. The purpose of this trial is to determine whether olmesartan medoxomil is effective at both treatment of coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA. This study is a prospective, single-center, open-label, randomized controlled clinical trial aimed at exploring the efficacy of olmesartan medoxomil on coronary atherosclerosis and EAT. A total of 194 patients with coronary stenosis greater than 30 % and less than 70 % detected by CCTA will be randomly divided into olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). The primary outcome measures include coronary atherosclerosis progression and EAT volume reduction, as detected by CCTA at 12 months. The secondary outcome measures include the levels of blood lipids, glucose, high-sensitivity C-reactive protein, IL-6, monocyte chemotactic protein 1, TNF-α, matrix metalloproteinase 9, NO, endothelin 1, adiponectin, and leptin at baseline and after 6 and 12 months. Treatments aimed at reducing EAT volume can eventually achieve an antiatherosclerotic effect. This is the first trial designed to explore the effect of olmesartan medoxomil on both coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA. ClinicalTrials.gov: NCT02360956 .
- 6 January 2016
- Published by Springer Nature in Trials
- Vol. 17 (1) , 1-8
Open AccessEfficacy study of olmesartan medoxomil on coronary atherosclerosis progression and epicardial adipose tissue volume reduction in patients with coronary atherosclerosis detected by coronary computed tomography angiography: study protocol for a randomized controlled trial
Epicardial adipose tissue (EAT) is a newly discovered independent risk factor for coronary atherosclerosis. There is a scarcity of information on the reduction of EAT volume to reduce atherosclerosis risk. Coronary computed tomography angiography (CCTA) has emerged as a noninvasive imaging method for the analysis of coronary atherosclerosis and EAT volume. The purpose of this trial is to determine whether olmesartan medoxomil is effective at both treatment of coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA. This study is a prospective, single-center, open-label, randomized controlled clinical trial aimed at exploring the efficacy of olmesartan medoxomil on coronary atherosclerosis and EAT. A total of 194 patients with coronary stenosis greater than 30 % and less than 70 % detected by CCTA will be randomly divided into olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). The primary outcome measures include coronary atherosclerosis progression and EAT volume reduction, as detected by CCTA at 12 months. The secondary outcome measures include the levels of blood lipids, glucose, high-sensitivity C-reactive protein, IL-6, monocyte chemotactic protein 1, TNF-α, matrix metalloproteinase 9, NO, endothelin 1, adiponectin, and leptin at baseline and after 6 and 12 months. Treatments aimed at reducing EAT volume can eventually achieve an antiatherosclerotic effect. This is the first trial designed to explore the effect of olmesartan medoxomil on both coronary atherosclerosis progression and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA. ClinicalTrials.gov: NCT02360956 .